NuScale
SMR
$11.96
-0.33%
NuScale Power Corporation is a pioneering developer of small modular reactor (SMR) technology, operating within the Renewable Utilities industry. The company is a pure-play technology leader, aiming to commercialize its proprietary, factory-built nuclear power modules to deliver safe, scalable, and carbon-free energy. The current investor narrative is dominated by extreme volatility and debate over its path to commercialization, with recent news highlighting a major strategic investor's exit, significant project delays, massive cash burn, and a stock price that has collapsed over 80% from highs, forcing investors to weigh a high-risk, long-duration bet on unproven technology against severe financial and execution risks.…
SMR
NuScale
$11.96
Related headlines
Investment Opinion: Should I buy SMR Today?
Rating: Sell. The core thesis is that NuScale's catastrophic fundamental deterioration, extreme valuation, and reliance on speculative future success create an asymmetric risk/reward profile skewed heavily to the downside.
Supporting evidence is overwhelmingly negative: Revenue collapsed 94.7% YoY to $1.81 million, gross margin turned negative at -3.37%, and the company burns over $200M quarterly in operating cash flow. Despite this, the market values it at a PS ratio of 73.7x, an astronomical multiple even for a growth stock, and an EV/Sales of 84.5x. The stock's beta of 2.28 confirms extreme volatility, and the exit of strategic investor Fluor removes a key pillar of support.
The thesis would change if the company announced a major, funded utility contract that provides a credible path to the $1.2B analyst revenue forecast, or if it secured non-dilutive financing that extends its runway by several years. Conversely, a failure to show sequential revenue growth or a dilution event would reinforce the Sell rating. The stock is profoundly overvalued relative to its current fundamentals and near-term prospects.
Sign up to view all
SMR 12-Month Price Forecast
The 12-month outlook is dominated by high risk of dilution and further fundamental disappointment. The base case (50% probability) is a volatile hold pattern supported by capital raises, but the bear case (35% probability) of a breakdown to new lows is nearly as likely. The bull case requires a near-miracle contract win and is given low odds (15%). The stance is bearish due to the severe mismatch between valuation and reality, though confidence is only medium due to the stock's high beta and potential for sharp, news-driven rallies. The stance would upgrade to neutral only upon demonstration of sequential revenue growth and a secured, multi-year funding runway without catastrophic dilution.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on NuScale's 12-month outlook, with a consensus price target around $15.55 and implied upside of +30.0% versus the current price.
Average Target
$15.55
6 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
6
covering this stock
Price Range
$10 - $16
Analyst target range
Analyst coverage is limited, with only 6 analysts providing estimates, and the provided data lacks a consensus price target or recommendation breakdown, indicating insufficient analyst coverage to derive a clear consensus sentiment. The absence of robust coverage is typical for a small-cap, pre-commercialization company like NuScale and implies higher volatility and less efficient price discovery, as the stock is driven more by speculative narratives than institutional analysis. The available institutional ratings from recent months show a mix of actions, including 'Sell' from Citigroup, 'Neutral' from UBS and Goldman Sachs, and 'Buy' from Canaccord Genuity, reflecting high uncertainty and a lack of conviction; the wide dispersion in analyst views, from Sell to Buy, signals profound disagreement on the company's prospects and timeline, which is a hallmark of a high-risk, binary investment story.
Bulls vs Bears: SMR Investment Factors
The evidence heavily favors the bear case, as fundamental deterioration (94.7% revenue decline, massive cash burn) is severe and current, while bull points rely on distant potential and oversold technicals. The single most important tension in the investment debate is the timeline to commercialization. Bulls must believe NuScale can survive a multi-year cash burn, secure new financing without crippling dilution, and finally generate the $1.2+ billion in revenue analysts forecast. Bears see the recent revenue collapse and Fluor's exit as early signals that this timeline is slipping or may never materialize, making the current $5.2 billion valuation untenable.
Bullish
- Zero Debt, Strong Liquidity: The company has a pristine balance sheet with zero debt and a robust current ratio of 4.30. This provides a critical buffer to fund its massive cash burn and navigate the long path to commercialization without immediate solvency risk.
- Pure-Play SMR Technology Leader: NuScale is a first-mover in small modular reactor technology, a key solution for carbon-free, baseload power. The market's $5.17 billion valuation, despite minimal revenue, reflects a significant premium for this long-term potential in the energy transition.
- Oversold Technical Condition: The stock is down 72.94% over six months and trades at just 21% of its 52-week range, near its low of $8.85. This extreme sell-off may have priced in near-term risks, creating a potential entry point for speculative capital if sentiment shifts.
- Analyst Revenue Forecasts Imply Massive Growth: Analyst consensus estimates project average revenue of $1.21 billion, a staggering increase from the current $1.81 million quarterly run-rate. This embedded expectation, if met, would justify a re-rating, though it is highly speculative.
Bearish
- Catastrophic Revenue Collapse: Q4 2025 revenue of $1.81 million represents a 94.72% year-over-year decline, plummeting from $13.38 million in Q1 2025. This indicates the core business model of selling reactor technology has stalled dramatically, calling near-term viability into question.
- Extreme Valuation Despite No Profits: The stock trades at a Price-to-Sales ratio of 73.70x and an EV/Sales of 84.51x on negligible revenue, while posting a net margin of -11.30%. This valuation embeds a massive success premium with no margin for error on execution.
- Massive, Unsustainable Cash Burn: The company burned -$203.70 million in operating cash flow in Q4 2025 alone, with trailing twelve-month free cash flow at -$460.12 million. With zero revenue growth, survival is entirely dependent on dilutive equity financing.
- Key Strategic Investor Exited: Recent news confirms Fluor has completed its exit from NuScale. The loss of a major strategic and financial backer is a severe blow to credibility and removes a source of potential funding and project expertise.
SMR Technical Analysis
The prevailing price trend is a severe and sustained downtrend, with the stock down 72.94% over the last six months and 29.05% over the past year. The current price of $12.14 sits near the lower end of its 52-week range, trading at approximately 21% of the range between its 52-week low of $8.85 and high of $57.42, indicating the stock is deeply oversold and may represent a value opportunity, albeit with high risk of further declines. Recent short-term momentum shows a significant divergence, with the stock up 18.32% over the past month against the backdrop of the longer-term collapse, suggesting a potential oversold bounce or short covering; however, this positive 1-month move is dwarfed by the 30.55% decline over the last three months, indicating the bounce is fragile within a powerful downtrend. Key technical support is clearly defined at the 52-week low of $8.85, while resistance looms far above near the 52-week high of $57.42; a breakdown below $8.85 would signal a new phase of capitulation, while any sustained move higher faces immense overhead supply. The stock's beta of 2.279 confirms it is more than twice as volatile as the broader market, which is critical for risk management as it implies amplified moves in both directions.
Beta
2.25
2.25x market volatility
Max Drawdown
-82.9%
Largest decline past year
52-Week Range
$9-$57
Price range past year
Annual Return
-44.7%
Cumulative gain past year
| Period | SMR Return | S&P 500 |
|---|---|---|
| 1m | +24.8% | +8.2% |
| 3m | -14.5% | +9.0% |
| 6m | -46.7% | +10.5% |
| 1y | -44.7% | +26.5% |
| ytd | -26.7% | +8.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
SMR Fundamental Analysis
Revenue growth is highly erratic and currently in a state of collapse, with Q4 2025 revenue of just $1.81 million representing a catastrophic year-over-year decline of 94.72%. The multi-quarter trend shows revenue plummeting from $13.38 million in Q1 2025 to the current minimal level, indicating the core business of selling reactor technology and services has stalled dramatically, which calls the near-term commercial viability of its model into question. The company is deeply unprofitable, with a Q4 2025 net loss of $50.83 million and a gross margin of -3.37%, reflecting a complete inability to cover its cost of revenue; while the gross margin was positive in prior quarters (e.g., 52.35% in Q1 2025), the recent plunge into negative territory is alarming and suggests revenue recognition issues or one-time costs overwhelming a tiny revenue base. Profitability metrics are dire, with a trailing twelve-month free cash flow of -$460.12 million and a return on equity of -30.44%, underscoring the massive cash burn required to fund pre-revenue development. The balance sheet shows a strong current ratio of 4.30 and zero debt, providing near-term liquidity, but the relentless cash consumption from operations (-$203.70 million in Q4 2025 operating cash flow) means the company is entirely dependent on external equity financing to survive, creating persistent dilution risk for shareholders.
Quarterly Revenue
$1808000.0B
2025-12
Revenue YoY Growth
-0.94%
YoY Comparison
Gross Margin
-0.03%
Latest Quarter
Free Cash Flow
$-460117999.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is SMR Overvalued?
Given the company's consistent net losses and negative EBITDA, the primary valuation metric selected is the Price-to-Sales (PS) ratio. The trailing PS ratio is an astronomical 73.70x, while the Enterprise Value-to-Sales ratio is even higher at 84.51x, reflecting a market capitalization of $5.17 billion being applied to negligible revenue, which signals the market is pricing in massive future sales growth that is far from certain. Peer comparison is challenging due to the company's unique pre-revenue status, but such extreme sales multiples are unheard of in the utilities sector and indicate a speculative premium based solely on the potential of its SMR technology rather than current fundamentals. Historically, the stock's own valuation has compressed dramatically but remains elevated; the current PS ratio of 73.70x is down from over 1,283x at the end of Q4 2025, yet it still sits near the top of its multi-year range when considering its revenue base, suggesting the market's expectations, while lowered, still embed a significant success premium that leaves little margin for error.
PE
-6.5x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -75x~-3x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-6.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are extreme. The company's revenue base has effectively vanished, declining 94.7% YoY to $1.81 million in Q4 2025, while it burns cash at a rate of over $200 million per quarter. With a trailing FCF of -$460 million, the company is entirely reliant on external equity markets for survival, guaranteeing future shareholder dilution. The recent plunge into a negative gross margin of -3.37% is particularly alarming, suggesting it cannot cover the basic cost of its dwindling revenue.
Market & Competitive Risks are pronounced. The stock's valuation of 73.7x PS is a speculative bubble by any utility sector standard, leaving it highly vulnerable to multiple compression if growth timelines extend. With a beta of 2.28, the stock is more than twice as volatile as the market, amplifying downside during risk-off periods. Competitive and regulatory risks are high, as seen in recent news where a UK funding announcement benefited a competitor more than NuScale, highlighting the fickle nature of government support.
Worst-Case Scenario involves a failure to secure necessary financing amid continued project delays and customer attrition. This could lead to a liquidity crisis, forcing the company to sell assets or seek bankruptcy protection. The realistic downside is severe; a break below the 52-week low of $8.85 would signal a new phase of capitulation. From the current price of $12.14, this implies a potential loss of -27%. In a full failure scenario where the technology is abandoned, the stock could approach zero, representing a total loss of capital.
FAQ
The key risks are, in order of severity: 1) Financial Risk: The company burns over $200 million per quarter with no profits and relies on dilutive equity raises to survive (TTM FCF: -$460M). 2) Execution/Commercialization Risk: Revenue collapsed 94.7% YoY, showing the business model is not currently viable; project delays and the exit of key partner Fluor exacerbate this. 3) Valuation Risk: The PS ratio of 73.7x is unsustainable and will compress violently if growth timelines slip. 4) Market Risk: With a beta of 2.28, the stock will fall more than twice as hard as the market during downturns.
The 12-month forecast is a wide range reflecting extreme uncertainty. The base case (50% probability) sees the stock trading between $9 and $15, as it raises capital and treads water. The bear case (35% probability) could see it fall to $5-$9 if liquidity concerns mount and it breaks below its 52-week low of $8.85. The bull case (15% probability) could drive a rally to $25-$35 on a major contract win. The most likely scenario is the base case, which assumes the company survives via dilution but fails to demonstrate commercial progress, leading to continued volatility within a downtrend.
SMR is profoundly overvalued based on any traditional fundamental metric. With a Price-to-Sales ratio of 73.70x and an EV/Sales of 84.51x applied to negligible and collapsing revenue, the market is pricing in a near-perfect future where the company achieves analyst forecasts of over $1.2 billion in revenue. This represents a massive speculative premium. Compared to its own history, the PS ratio has compressed from over 1,283x but remains astronomically high. The valuation implies the market expects flawless execution and rapid commercialization, a scenario with very low probability given current headwinds.
For the vast majority of investors, SMR is not a good stock to buy at current levels. It is a speculative, binary bet on unproven technology with catastrophic near-term fundamentals, including a 94.7% revenue decline and a quarterly cash burn over $200 million. The extreme valuation (PS ratio of 73.7x) leaves massive downside risk if execution falters. It could only be considered a high-risk, high-reward speculation for a very small portion of a portfolio by investors who deeply understand nuclear technology risks and have a 5-10 year horizon, willing to potentially lose their entire investment.
SMR is unsuitable for short-term trading for all but the most sophisticated and risk-tolerant traders due to its extreme volatility (beta 2.28) and low liquidity. It is theoretically a long-term investment, but the 'long-term' here is measured in decades, not years, as the company is in a pre-revenue development phase with no clear path to profitability. It pays no dividend and offers no earnings visibility. If an investor has conviction in the technology, a minimum holding period of 5-10 years is necessary to see through the development cycle, but they must be prepared for the stock to go to zero. For most, it is not a suitable investment for any horizon.